Esperion to Acquire Corstasis, Expanding Cardiovascular Franchise with Enbumyst(TM)
ESPR has more than doubled off its 52-week low of $0.693.
Summary
Esperion Therapeutics has announced a definitive agreement to acquire Corstasis Therapeutics, a move poised to significantly expand its cardiovascular franchise. The acquisition will integrate Enbumyst(TM) (bumetanide nasal spray) into Esperion's product portfolio, enhancing its offerings in a critical therapeutic area. This strategic transaction is expected to strengthen Esperion's market position and provide a new growth driver. Traders will be looking for further details on the financial terms of the deal and the potential market impact of Enbumyst(TM).
At the time of this announcement, ESPR was trading at $3.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $781.7M. The 52-week trading range was $0.69 to $4.18. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.